Finerenone Patent Expiration

1. Kerendia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436180 BAYER HLTHCARE Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
Apr, 2029

(4 years from now)

USRE49826 BAYER HLTHCARE Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient
Jul, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-279) Sep 01, 2025
New Chemical Entity Exclusivity(NCE) Jul 09, 2026

NCE-1 date: 09 July, 2025

Market Authorisation Date: 09 July, 2021

Treatment: NA

Dosage: TABLET

More Information on Dosage

KERENDIA family patents

Family Patents